Previous 10 | Next 10 |
Guardant Health (NASDAQ:GH): Q3 GAAP EPS of -$1.06 misses by $0.12. Revenue of $94.78M (+27.1% Y/Y) beats by $2.19M. Press Release Reported 22,806 tests to clinical customers and 4,839 tests to biopharmaceutical customers in the third quarter of 2021, representing an increase of 35% and 58%, ...
Achieved record revenue of $94.8 million Growth of 35% and 58% year over year in clinical and biopharma volumes, respectively Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its propri...
Increased accessibility to Guardant Health’s liquid biopsy testing will enable clinicians to personalize treatments more accurately for patients with late-stage cancer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and The Royal Marsden NHS Foun...
This study indicates Guardant Health’s blood test could provide meaningful clinical performance in an average risk screening population Guardant Health, Inc. (Nasdaq: GH), presents data at the American College of Gastroenterology Annual Scientific Meeting being held f...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors. “We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on our mission of conquering c...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Higher yields as well as uncertainty over inflation, supp...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after market close on Thursday, November 4, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30...
1,000-patient prospective study in 11 solid tumors will monitor ctDNA levels up to five years Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE) study, a 1,000-pati...
Shares of healthcare company Guardant Health (NASDAQ: GH) are down 14.2% as of mid-session today on the heels of unconfirmed reports that it's interested in acquiring peer and indirect rival NeoGenomics (NASDAQ: NEO) . Only citing "people familiar with the matter," Bloom...
Most people want to be financially secure in retirement. To achieve that goal, many shrewdly turn to the stock market. Investing in stocks allows your money to grow substantially more than, say, in a traditional savings account. Of course, the stock market also comes with risks, but picking...
News, Short Squeeze, Breakout and More Instantly...
2024-05-11 09:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highligh...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...